Physician profile
Collin Pieper
NPI 1093464539
$2,640.97
in general payments reported to CMS, 2019-2025
15 companies · $1,208 in 2025
The $1,208 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $49.33 · 2024: $1,383 · 2025: $1,208.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,641.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,640.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $531.04 | 2023-2025 | |
| Lilly USA, LLC | $466.25 | 2023-2025 | Ebglyss |
| Novartis Pharmaceuticals Corporation | $384.68 | 2024-2025 | |
| Genzyme Corporation | $308.95 | 2024-2025 | |
| Pfizer INC. | $276.23 | 2024-2025 | |
| Janssen Scientific Affairs, LLC | $248.67 | 2024-2025 | Tremfya |
| Boehringer Ingelheim Pharmaceuticals, INC. | $87.91 | 2024 | Spevigo |
| Paratek Pharmaceuticals, INC. | $79.63 | 2024-2025 | Nuzyra |
| Janssen Biotech, INC. | $63.38 | 2024-2025 | Tremfya |
| Dermavant Sciences, INC. | $56.17 | 2024 | Vtama |
| Regeneron Healthcare Solutions, INC. | $38.52 | 2025 | Dupixent |
| E.R. Squibb & Sons, L.L.C. | $29.05 | 2025 | Sotyktu |
| Krystal Biotech INC | $25.44 | 2025 | Vyjuvek |
| Leo Pharma INC. | $23.44 | 2025 | Adbry |
| Mallinckrodt Hospital Products INC. | $21.61 | 2024 | Acthar |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Collin Pieper listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.